Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCellular and Molecular

Adenylate cyclase-cAMP-protein kinase A signaling pathway inhibits endothelin type A receptor-operated Ca2+ entry mediated via TRPC6 channels.

Takahiro Horinouchi, Tsunaki Higa, Hiroyuki Aoyagi, Tadashi Nishiya, Koji Terada and Soichi Miwa
Journal of Pharmacology and Experimental Therapeutics October 14, 2011, jpet.111.187500; DOI: https://doi.org/10.1124/jpet.111.187500
Takahiro Horinouchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsunaki Higa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroyuki Aoyagi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadashi Nishiya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koji Terada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soichi Miwa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Receptor-operated Ca2+ entry (ROCE) via TRPC6 (transient receptor potential canonical channel 6) is an important machinery for an increase in intracellular Ca2+ concentration triggered by activation of Gq protein-coupled receptors. TRPC6 is phosphorylated by various protein kinases including protein kinase A (PKA). However, the regulation of TRPC6 activity by PKA is still controversial. The purpose of this study is to elucidate the role of adenylate cyclase/cAMP/PKA signaling pathway in regulation of Gq protein-coupled endothelin type A receptor (ETAR)-mediated ROCE via TRPC6. For this purpose, HEK293 cells stably co-expressing human ETAR and TRPC6 (wild-type) or its mutants possessing a single point mutation of putative phosphorylation sites for PKA were used to analyze ROCE and amino acids responsible for PKA-mediated phosphorylation of TRPC6. Ca2+ measurements with thapsigargin-induced Ca2+-depletion/Ca2+-restoration protocol to estimate ROCE showed that stimulation of ETAR induced marked ROCE in HEK293 cells expressing TRPC6 compared with control cells. The ROCE was inhibited by forskolin and papaverine to activate cAMP/PKA pathway, while it was potentiated by Rp-8-Br-cAMP, a PKA inhibitor. Inhibitory effects of forskolin and papaverine were partially cancelled by replacing Ser28 (TRPC6S28A) but not Thr69 (TRPC6T69A) of TRPC6 with alanine. In vitro kinase assay with Phos-tagTM biotin to determine phosphorylation level of TRPC6 revealed that wild-type and mutant (TRPC6S28A and TRPC6T69A) TRPC6 proteins were phosphorylated by PKA, but the phosphorylation level of these mutants was lower (about 50%) than that of wild-type. These results suggest that TRPC6 is negatively regulated by PKA-mediated phosphorylation of Ser28 but not of Thr69.

  • cAMP
  • endothelin receptors
  • phosphorylation
  • protein kinase A
  • transient receptor potential (TRP) receptors
  • Received August 31, 2011.
  • Revision received October 13, 2011.
  • Accepted October 13, 2011.
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 385 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 385, Issue 3
1 Jun 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Adenylate cyclase-cAMP-protein kinase A signaling pathway inhibits endothelin type A receptor-operated Ca2+ entry mediated via TRPC6 channels.
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCellular and Molecular

Adenylate cyclase-cAMP-protein kinase A signaling pathway inhibits endothelin type A receptor-operated Ca2+ entry mediated via TRPC6 channels.

Takahiro Horinouchi, Tsunaki Higa, Hiroyuki Aoyagi, Tadashi Nishiya, Koji Terada and Soichi Miwa
Journal of Pharmacology and Experimental Therapeutics October 14, 2011, jpet.111.187500; DOI: https://doi.org/10.1124/jpet.111.187500

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCellular and Molecular

Adenylate cyclase-cAMP-protein kinase A signaling pathway inhibits endothelin type A receptor-operated Ca2+ entry mediated via TRPC6 channels.

Takahiro Horinouchi, Tsunaki Higa, Hiroyuki Aoyagi, Tadashi Nishiya, Koji Terada and Soichi Miwa
Journal of Pharmacology and Experimental Therapeutics October 14, 2011, jpet.111.187500; DOI: https://doi.org/10.1124/jpet.111.187500
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • pH-dependent GPR4 antagonist
  • Antifibrotic DRD1 escapes TGFβ-mediated repression
  • Chlorogenic Acid Inhibits Breast Cancer Metastasis
Show more Cellular and Molecular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics